Normothen (Doxazosin Mesilate)

Doxazosin mesilate, the active ingredient in Normothen, is a alpha-1 adrenergic blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and for relief of urinary symptoms associated with benign prostatic hyperplasia in adult patients. GNH USA supplies Normothen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Normothen, an alpha‑1 adrenergic blocker, is used in conditions where vascular tone or prostatic smooth‑muscle tone is a therapeutic target.

Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. Benign prostatic hyperplasia: relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Elevated blood pressure: assists in achieving target blood pressure levels when combined with other antihypertensives.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or tiredness - Nasal congestion or runny nose - Peripheral edema - Nausea or abdominal discomfort

Serious or Rare Side Effects: - Severe hypotension or syncope - Priapism (prolonged erection) - Liver function abnormalities - Allergic reactions such as rash or angioedema - Rapid heart rate or arrhythmia

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: check baseline and periodic readings. - Hepatic impairment: dose may need adjustment; monitor liver enzymes. - Concomitant antihypertensives: risk of additive hypotension. - Prostate cancer: use with caution; evaluate disease status. - Renal impairment: assess renal function and adjust dose if needed. - Store at ambient temperature: keep in the original container, protect from moisture.

Doxazosin may interact with several drug classes; awareness helps avoid adverse events.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): risk of severe hypotension. - Other potent antihypertensives (e.g., clonidine, nitroprusside): additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension; monitor electrolytes. - Beta‑blockers: combined effect on blood pressure; observe heart rate. - NSAIDs: may blunt antihypertensive response; assess renal function.